The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology

URL:  https://boards.fool.com/well-usually-there-is-a-trial-or-two-that-we-can-34559779.aspx

Subject:  Re: NKTX Date:  7/12/2020  7:08 AM
Author:  Fuma102 Number:  25376 of 25442

Well, usually there is a trial or two that we can look into! Not so much here with NKarta, so we had to get fancy.

In their presentation, the list of cited papers on page 17, those are actually hyperlinks to the papers. They bachnova 42 patient paper from 2014:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064329/

"Later grade 3 to 5 toxicities, which included infection or fevers (n = 5), cytomegalovirus viremia (n = 1), alveolar hemorrhage (n = 2), pulmonary events (n = 2), pleural effusion (n = 1), candidemia (n = 1), fungal pneumonia (n = 1), atrial fibrillation (n = 1), left ventricular dysfunction (n = 1), typhlitis (n = 1), meningitis (n = 1), and Epstein-Barr virus (EBV)-associated lymphoma (n = 1), were most likely related to prolonged cytopenias and immune suppression"

Honestly not sure how this compares to stemcell transplant, but that seems like a list that gets you a black box warning 😳😳😳
Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us